Smartbiotic
Offers personalized antibiotic recommendations to better prescribe and reduce resistance.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | N/A | Seed | |
| Total Funding | 000k | ||
| USD | 2023 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Dealroom estimates
Related Content
Smartbiotic, founded in 2023 by Xavier Trallero Giner and Sergi Tres, is a biotechnology firm specializing in the development of antimicrobial solutions aimed at combating bacterial resistance. The company's core technology revolves around a proprietary platform that leverages artificial intelligence to design and create 'smart' antimicrobial molecules. These molecules are engineered to specifically target and eliminate multidrug-resistant bacteria, offering a potential alternative to conventional antibiotics. The founders' backgrounds are rooted in science and business; Xavier Trallero Giner holds a PhD in Biomedicine, while Sergi Tres brings experience from the business and finance sectors, creating a complementary leadership team to drive both the scientific and commercial aspects of the venture. Their journey began with a shared concern for the growing global health crisis of antibiotic resistance, leading them to establish Smartbiotic to accelerate the discovery of new antibacterial agents.
The business operates within the pharmaceutical and biotechnology markets, focusing on a B2B model. Its primary clients are pharmaceutical companies and research institutions seeking novel compounds to develop into new drugs. Smartbiotic's revenue model is based on a combination of research collaborations, licensing agreements for its technology platform, and milestone payments as its proprietary molecules advance through the drug development pipeline. The company's main offering is its AI-powered platform which significantly shortens the discovery phase of new antimicrobial drugs, a process that traditionally is time-consuming and costly. This platform analyzes vast biological datasets to predict effective molecular structures, which are then synthesized and tested. This approach allows for the rapid generation of highly selective and potent antimicrobial candidates, addressing a critical need for new treatments against resistant pathogens.
Keywords: antimicrobial resistance, drug discovery, artificial intelligence, biotechnology, bacterial infections, pharmaceutical development, molecular design, multidrug-resistant bacteria, synthetic biology, therapeutic agents